Volume 16, Number 11—November 2010
Research
Lymphotropism of Merkel Cell Polyomavirus Infection, Nova Scotia, Canada
Sonia Toracchio, Annette Foyle, Vojtech Sroller1, Jon A. Reed, Jun Wu, Claudia A. Kozinetz, and Janet S. Butel
Table 5
Clinical outcomes for lymphoma patients over a 5-year period, Nova Scotia, Canada*
| Characteristics | No. (%) MCPyV positive | No. (%) MCPyV negative | p value |
|---|---|---|---|
| Disease stage† | |||
| I | 2 (28.6) | 35 (35.4) | |
| II | 2 (28.6) | 14 (14.1) | |
| III | 0 | 11 (11.1) | |
| IV |
3 (42.9) |
39 (39.4) |
0.62 |
| Patient survival | |||
| Alive in remission | 3 (42.9) | 38 (35.5) | |
| Alive with disease | 1 (14.3) | 23 (21.5) | |
| Died from disease | 3 (42.9) | 46 (43.0) | 0.88 |
*The 5-year period refers to the time frame for each patient from time of diagnosis until follow-up 5 years later. MCPyV, Merkel cell polyomavirus.
†Clinical stage of disease at time of lymphoma diagnosis; information was not available for 8 MCPyV-negative patients.
